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Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous envi-
ronmental and food contaminants with known or suspected
carcinogenic properties. In this study, we have evaluated whether
PAHs activate the early growth response (EGR-1) gene and bind
to peroxisome proliferator-activated receptor alpha (PPARa) and
delta (PPARb/d) in cell culture systems. Luciferase reporter
systems were employed and several PAHs were evaluated for
their ability to activate EGR-1 and PPARs. Some PAHs enhanced
EGR-1 expression and activated PPARa and PPARb. Among
them, benz(a)anthracene was found to act as a relatively potent
activator of PPARa and PPARb/d, and to significantly enhance
EGR-1 transcription. These in vitro assays were confirmed by
Western blot analysis, using cell lysates of tissue samples from
mouse trapped at a highly contaminated Superfund site in the
Chattanooga Creek floodplain in Chattanooga, Tennessee. We
have found that a PPAR target gene, glycogen synthase kinase-3b
(GSK-3b), was down-regulated and EGR-1 was up-regulated in
the mouse samples of Chattanooga Creek. In addition, select
PAHs repressed GSK-3b and induced CYP4A in FaO rat
hepatoma cells. In conclusion, PAHs activate PPARa and
PPARb/d, and up-regulate EGR-1 expression in vitro as well as
in vivo. These data may provide a diversity of PAH activity in
several biological pathways.
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Polycyclic aromatic hydrocarbons (PAHs) are toxic and
ubiquitous environmental pollutants. They are generally
formed and emitted into the environment as a result of
incomplete combustion of fossil fuels, wood, and other organic
materials and from industrial processes. Humans and animals
are exposed to PAHs from air, water, dietary, and occupational
sources, and also from cigarette smoke. Their very long
biological half-lives in combination with biological effects at
very low concentrations have caused health concerns about
carcinogenicity (Rubin, 2001), teratogenicity (Couture et al.,
1990; Incardona et al., 2004), and cardiovascular disease
(Gustavsson et al., 1996, 2001; Thirman et al., 1994). Although
many reports focus on elucidating the molecular mechanism of
PAHs in several diseases, pathways other than aryl hydrocar-
bon receptor (AhR) activation have received little attention.
Many chronic diseases, including cancer and cardiovascular
diseases have been linked to heredity and/or the environment,
which can either enhance or inhibit the disease process. One
such molecular link between disease and the environment is
early growth response-1 (EGR-1, also known as NGFI-A,
Zif268, Krox24, and Tis8). EGR-1 is the prototypical member
of a family of zinc finger transcription factors that includes
at least three other members, EGR-2, -3, and -4. EGR-1 is
especially induced by a range of physiological and environ-
mental stimuli including growth factors, cytokines, ultraviolet
light, ionizing radiation, and mechanical injury (Gashler and
Sukhatme, 1995; Khachigian and Collins, 1998). EGR-1
appears to be critically involved in several diseases including
angiogenesis and tumor formation. Alteration in expression
could contribute to the deleterious effects of PAH exposure.
Recently, Martinez et al. reported that halogenated aromatic
hydrocarbon, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), in-
duces EGR-1 expression in human lung carcinoma cells
(Martinez et al., 2004). However, expression of EGR-1 in
nonneoplastic cells underlies diverse pathophysiological re-
sponses such as survival responses to damaging irradiation
(Huang et al., 1999), development of vascular occlusion in
arteriosclerosis (Silverman and Collins, 1999), and formation
of severe pulmonary emphysema (Zhang et al., 2000). In
addition to these diverse actions, expression of EGR-1 is
commonly down-regulated in tumor cells in contrast with their
normal tissue counterparts (Calogero et al., 2004; Hao et al.,
2002; Huang et al., 1997; Levin et al., 1995; Shozu et al.,
2004). However, EGR-1 is expressed at a higher level and
promotes cell growth in prostate cancer when compared with
normal tissues (Eid et al., 1998; Thigpen et al., 1996). Thus,
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EGR-1 has multiple functions in tumorigenesis, and the exact
biological function of EGR-1 may be dependent on cell context
as well as tissue types (Baek et al., 2004). Nonetheless, the
EGR-1’s role in vascular disease has been firmly established by
the fact that EGR-1 controls the expression of several genes
implicated in the pathogenesis of atherosclerosis and restenosis
(Breslow, 1996; Harja et al., 2004; McCaffrey et al., 2000;
Silverman and Collins, 1999).
Peroxisome proliferator activated receptors (PPARs) are
another molecular link between chronic disease and the
environment. PPARs are members of the nuclear receptor
superfamily and exist as three subtypes designated a, b (or d),
and c. Among those, PPARa activation is responsible for
the pleiotropic effects of peroxisome proliferator such as
enzyme induction, peroxisome proliferation, liver enlargement,
and tumors (Klaunig et al., 2003). PPARa also plays a critical
role in regulation of cellular uptake and b-oxidation of fatty
acids (Berger and Moller, 2002; Marx et al., 2004). In contrast,
PPARd (also known as PPARb) is widely expressed with
relatively higher levels in brain, colon, and skin. Although
there have been extensive studies on PPARa, much less is
known about the function of PPARd. Nonetheless, recent
studies suggest that PPARd plays a role in colon cancer (Gupta
et al., 2004; He et al., 1999; Wang et al., 2004), and
preadipocyte proliferation (Hansen et al., 2001).
We hypothesized that transcription factors, EGR-1 and
PPARs may link environmental toxic compounds to human
diseases. The aim of this study is to determine whether
PAHs affect EGR-1 and PPARs activity and to identify the
different activity of PAHs in reporter system. In this study,
fifteen PAHs, which are commonly found in the environment,
were examined as potential activators of PPARa or PPARb/d,
and inducer of EGR-1 gene expression in A549 human lung
adenocarcinoma cells and HCT-116 human colorectal adeno
carcinoma cells. The luciferase reporter genes were used to
measure the activity of PPARs and transactivation of the EGR-1
promoter. We have demonstrated that some PAHs may
activate PPARa and PPARb/d, and transactivate EGR-1 pro-
moter activity. Among those, benz(a)anthracene (BaA) induces
EGR-1 and PPAR activation in culture systems. Furthermore
feral mice (Peramyscus gossypinus) trapped along the flood-
plain of a Superfund site with high levels of PAH contamina-
tion demonstrated significant up-regulation of EGR-1 and
down-regulation of GSK-3b, a PPAR target gene. These data
provide evidence for diverse effects of PAHs that may be
important in diseases linked to environmental pollution such as
cardiovascular disease and carcinogenesis.
MATERIALS AND METHODS
Cell culture and chemicals. A549 human lung adenocarcinoma cell lines
and HCT-116 human colorectal carcinoma cell lines were obtained from the
American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were
cultured in RPMI-1640 medium supplemented with 10% FBS and 10 lg/ml
gentamycin. HCT-116 cells were cultured in Modified McCoy 5A medium
supplemented with 10% FBS and 10 lg/ml gentamycin. FaO rat hepatoma cell
lines were generously provided by Dr. Seong-Jin Kim (National Cancer
Institute, Bethesda, MD) and were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% FBS and 10 lg/ml gentamycin. All the PAHs
were purchased from Sigma-Aldrich (St. Louis, MO) and completely dissolved
in DMSO.
Plasmids. EGR-1 promoter (1260 to þ35) linked to the luciferase gene
(pEGR1260-Luc) was described previously (Baek et al., 2003). The plasmids
used for studying PPARa and PPARb/d activators were a reporter gene
containing four copies of a Gal4 binding site (MH10034-TK-Luc) and
chimeric receptors (pCMX-Gal-mPPARa-LBD for PPARa and pCMX-Gal-
mPPARd-LBD for PPARd). In this system, when a compound binds to the
ligand binding domain (LBD) from PPARa or PPARd of the chimeric receptor
(pCMX-Gal4-mPPARa-LBD or pCMX-Gal-mPPARd-LBD), then the DNA
binding domain of the yeast Gal4 (denoted as Gal) binds to co-transfected Gal4
binding site and initiates transcription of the firefly luciferase (Luc). A reporter
plasmid containing three copies of the PPAR response element (PPRE33-TK-
Luc) and a mouse PPARa cDNA (pCDNA3-mPPARa) were previously
described (Nixon et al., 2003). This system directly measures activation of
PPARa via transcriptional activation of the luciferase reporter gene as a result
of PPARa binding to the PPAR response element (PPRE). All the PPAR and
PPAR reporter plasmids were generously provided by Dr. Ronald M. Evans
(Howard Hughes Medical Institute, CA).
Transient transfections and luciferase reporter assays. Cells (1 3 105
cells/well) were cultured in twelve-well plates in culture medium containing
10% FBS. After growth for 16 h, the internal control, 0.05 lg pRL-null
(Promega, WI) and 0.5 lg of the other plasmids were transfected using
LipofectAMINE (Life Technologies, Inc.) according to the manufacturer’s
protocol. After 24 h, the media were changed and the cells were treated with the
various PAHs dissolved in DMSO. The final concentration of DMSO did not
exceed 0.1% (v/v) in any of the samples. Treatments with PAHs were
performed under serum-free conditions. After 24 h treatment, the cells were
washed with PBS and harvested in 1X luciferase lysis buffer. The luciferase
activity was measured by a dual luciferase assay kit (Promega, WI), and
normalized to the internal control, pRL-null (renilla luciferase) activity.
Animal studies. Feral mice (Peramyscus gossypinus) were trapped along
the floodplain of the Chattanooga Superfund site and in a control site two miles
upstream from the contaminated section of creek. All animal procedures were
in compliance with the National Institute of Health guidelines on animal use
and were approved by the University of Tennessee Institutional Animal Care
and Use Committee. Traps were set each evening and checked each morning.
Trapped animals were transported to the laboratory and anesthetized with CO2.
After the chest cavities were opened, the mice were exsanguinated by cardiac
puncture and the distal aorta, heart and lungs perfused with phosphate buffered
saline (PBS) to remove clotted blood. Sections of heart, lung, and colon were
removed and snap-frozen in liquid nitrogen for Western blot analysis.
Western blot analysis. The level of protein expression was evaluated by
Western blot analysis. FaO cells were grown to 60–80% confluency in 6 cm
plates, followed by 24 h treatment of selected PAHs in the absence of serum.
Total cell lysates were isolated using RIPA buffer (13 phosphate-buffered
saline, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS)
containing proteinase inhibitor, and the soluble protein concentrations were
determined by BCA protein assay kit (Pierce, Rockford, IL). For feral mouse
tissues, frozen samples were lysed in ice-cold RIPA buffer as described above.
All lysate proteins were separated by SDS-PAGE and transferred for 1 h onto
nitrocellulose membrane (Osmonics Inc., MN). The blots were blocked for 1 h
with 5% skim milk in Tris-buffered saline and Tween 0.05% and probed with
GSK-3b (Cell Signaling, MA), EGR-1 (Santa Cruz Biotech., CA), CYP4A
(Affinity Bioreagent, Golden, CO), or Actin (Santa Cruz Biotech., CA)
antibody at 4C overnight. After washing with Tris-buffered saline and Tween
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0.05%, the blots were treated with horseradish peroxidase-conjugated second-
ary antibody for 1 h and washed several times. The signals were detected by
the enhanced chemiluminescence system (Amersham Biosciences, Arlington
Height, IL). The signal intensities were measured by NIH Image program
(Scion Corp., MD).
Statistical analysis. For luciferase activities of transient transfection
experiments, data were expressed as mean ± SD for at least three independent
repeats. For quantitative analyses, analysis of variance (ANOVA) with Tukey’s
multiple comparison test or t-test was used to compare mean values. SAS for
Windows (9.1) (SAS Institute Inc., Cary, NC) statistical analysis software was
used. A p-value of less than 0.05 was considered significant.
RESULTS
We have selected fifteen PAHs, containing two, three, four,
or five aromatic rings. These PAHs were found to be in
the highest concentrations in the Superfund site in Chatta-
nooga, Tennessee (Elgayyar et al., manuscript in preparation).
Among these, benz(a)anthracene (BaA), benzo(a)pyrene
(BaP), benzo(b)fluoranthene (BbF), benzo(k)fluoranthene
(BkF), and chrysene (CHR) are considered to be carcinogenic,
whereas acenaphthene (ANY), anthracene (ANT), naphthalene
(NAP), pyrene (PYR), phenanthrene (PA), and triphenylene
(TP) are not considered to be carcinogenic according to WHO
(Table 1). A limited number of recent studies have shown
that fluoranthene (FA) is an experimental carcinogen (Hecht
et al., 1995).
Effects of PAHs on EGR-1 Activation
Several PAHs were examined for the induction of EGR-1
gene in A549 human lung carcinoma cell lines, which have
been shown to induce EGR-1 expression (Martinez et al.,
2004). The pEGR1260-Luc construct was transiently trans-
fected into A549 cells and the luciferase activity was measured
in the presence of PAHs. The pEGR1260-Luc construct (Fig.
1A) contains 1.2 kb of the EGR-1 promoter (Baek et al., 2005).
All the PAHs tested here showed a significant increase in
luciferase activity except BaP and TP (Fig. 1B). PA, BaA, and
PA demonstrated higher luciferase activity, and PA also
increased EGR-1 activity in 1 lM concentration (Fig. 1C).
As a positive control, sulindac sulfide (30 lM) was used in the
promoter assay (Baek et al., 2005), showing a 4-fold induction
of luciferase activity compared to vehicle treated sample.
Effects of PAHs on PPARa activation
In addition to cyctochrome p450 based biomarkers, perox-
isome proliferators have been used for a pollution biomarker
in aquatic organism (Cajaraville et al., 2003). Among those,
PPARa has received much attention from many researchers
since PPARa expression is tightly regulated by various
hormones. In addition, PPARa plays a pivotal role in tumor-
igenesis and atherogenesis (Klaunig et al., 2003; Marx et al.,
2004). Therefore, we have examined whether PAH compounds
activate PPARa. The luciferase reporter construct and expres-
sion vector (Fig. 2A) were co-transfected into HCT-116 cells
that have been shown a high transfection efficiency (Baek
et al., 2001). The cells were treated with 10 lM of various
PAHs for 24 h and luciferase activity was examined. The
TABLE 1
Characteristics of Polycyclic Aromatic Hydrocarbons Used in
This Study
Compound Structure
Molecular
weight Genotoxicity
Carcino-
genicity
AhR
activity
Acenaphthene 154 (?) (?)
Acenaphthylene 152 (?)
Anthracene 178 — — —
Benz(a)anthracene 228 þ þ þþ
Benzo(a)pyrene 252 þ þ þþ
Benzo(b)fluoranthene 252 þ þ þþþ
Benzo(k)fluoranthene 252 þ þ þþþ
Biphenylene 152
Chrysene 228 þ þ þþþ
Fluoranthene 202 þ (þ) þ
1-Methylanthracene 192
Naphthalene 128 — (?)
Phenanthrene 178 (?) (?)
Pyrene 202 (?) (?) þ
Triphenylene 228 þ ()
Note. Genotoxicity and carcinigenecity according to WHO, 1998: þ,
positive; , negative; ?, questionable; parentheses, result derived from small
database (WHO, 1998). AhR-mediated activity (Machala et al., 2001) value
for benzo(a)pyrene (and PAHs with similar effects) was arbitrarily set as þþ;
values þþþ and þ indicate PAHs with more or less significant effects than
benzo(a)pyrene; value of  indicates no effect.
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luciferase activity to PAH treatment was compared to that
of vehicle treatment. BaA was estimated as a strong activator
among PAHs tested here. Other PAHs showed slight increases
or little changes in luciferase activity (Fig. 2B). As a positive
control, Wy14643 was used in this system and we found around
55-fold induction of luciferase activity, compared to vehicle
treated samples (data not shown). Transfected cells were also
exposed to BaA and luciferase activity was significantly
increased in a dose dependent manner (Fig. 2C). It is important
to note that the results shown in Figure 2 reflect solely activator
activity with exogenous transfectants. Therefore, to examine
the transactivation of PPARa, A549 cells were transiently co-
transfected with a pPPRE33-TK-Luc and pCDNA3-mPPARa
expression vector (Fig. 3A), and then treated with vehicle,
and 1 or 10 lM of BaA. As shown in Figure 3B, we observed
a significant induction of luciferase activity in a dose dependent
manner, indicating that BaA binds to PPARa and transactivates
the gene containing PPRE sites in the promoter.
Effects of PAHs on PPARb/d activation
It has been suggested that PPARb/d may play an important
role in tumorigenesis and atherogenesis (Gupta et al., 2004; He
et al., 1999; Marx et al., 2004; Tong et al., 2000). PAH
compounds were tested for PPARb/d activity in HCT-116 cells
transiently transfected with pMH10034-TK-Luc and pCMX-
Gal4-mPPARd-LBD constructs (Fig. 4A). The PPARb/d
activity of each PAH was compared with vehicle. Interestingly,
treatment with BaA also induced strong luciferase activity
among PAHs tested here. However, other PAHs also slightly
increased luciferase activity, which is significant (Fig. 4B).
BaA also increased luciferase activity in a dose dependent
manner (Fig. 4C).
GSK-3b and EGR-1 Expression in the Presence of PAHs
CYP4A is induced by PPARa activation in liver tissue
(Johnson et al., 1996). GSK-3b is repressed when FaO rat
hepatoma cells are exposed to PPARa and PPARb/d ligands
(Vanden Heuvel et al., 2003). We have shown that some PAHs
are able to bind the PPARa and PPARb/d as an activator.
To determine whether PAHs affects PPARa downstream in FaO
cells, we performed Western blot analysis using cell lysates
prepared from FaO cells treated with BaA, BaP, or PA. As
shown in Figure 5A, all the PAHs tested increase CYP4A
expression and suppressed GSK-3b expression relative to
vehicle-treated cells. BaA was the relatively strong suppressor
of GSK-3b expression, whereas BaP or PA was the weak
suppressor. These data are consistent with previous data
showing that BaA is the relatively strongest PPARa and
PPARb/d activator, whereas BaP and PA are relatively weak
(Figs. 2 and 4). Next, we examined GSK-3b expression in vivo
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FIG. 1. PAH effects on EGR-1 expression. (A) Schematic diagram of pEGR1260-Luc construct. (B) A549 cells were exposed to PAHs after transfection with
a pERG1260-Luc construct. Cells were treated with 5 lM PA and 10 lM of all other PAHs for 24 h. Sulindac sulfide was used as a positive control for EGR-1
activator (Baek et al., 2004, 2005). Transfection efficiency for luciferase activity was normalized to the Renilla luciferase (pRL-null vector) activity. The y-axis
shows relative luciferase unit (firefly luciferase unit/Renilla luciferase unit) by the fold increase in PAH treatment over vehicle treatment. The results are expressed
as mean ± SD of three independent transfections and different letters indicate significant difference (Tukey’s multiple comparision test, p < 0.05). VEH, vehicle;
SS, sulindac sulfide; ANT, anthracene; BaA, benz(a)anthracene; BaP, benzo(a)pyrene; BbF, benzo(b)fluoranthene; BkF, benzo(k)fluoranthene; CHR, chrysene; FA,
fluoranthene; PA, phenanthrene; PYR, pyrene TP, triphenylene; ANY, acenaphthylene. (C) A549 cells were transfected and exposed to 1 lM, 5 lM of PA. The
luciferase activity was measured, and relative luciferase unit was shown at y-axis. t-test, **p < 0.01; ***p < 0.001, compared to vehicle.
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using feral mice (Peramyscuc gossypinus) trapped along the
floodplain of a highly contaminated area of the Chattanooga
Creek and also along a noncontaminated area. We evaluated
GSK-3b expression in colon, heart, and lung tissues of mice
from both areas. As shown in Figure 5B, GSK-3b was down-
regulated in heart but not lung from mice trapped in the
contaminated area of the Chattanooga Creek when compared to
mice trapped in the control area. However, GSK-3b was not
detected in colon tissue from both mice trapped from either
site. We also measured EGR-1 expression and found that EGR-
1 was induced in colon samples from mice trapped in the
Superfund site when compared to control. However, no EGR-1
was detected in heart or lung samples from either site. EGR-1
induction in the in vivo study is consistent with in vitro data,
showing that PAHs increase EGR-1 expression as assessed by
a reporter system (Fig. 1). Taken together, these results suggest
that some PAHs, particularly BaA activates PPARa and
PPARb/d, and alters the PPAR target gene expression such as
CYP4A and GSK-3b.
DISCUSSION
Humans and other living organisms are constantly exposed
to a large number of potentially toxic environmental
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FIG. 2. PAH effects ozn PPARa binding affinity. (A) Schematic diagram of pCMX-Gal4-mPPARa-LBD and pMH100X4-TK-Luc vector. (B) HCT-116 cells
were transfected with the vectors shown in Figure 2A, and the cells were treated with 10 lM of various PAHs indicated for 24 h. Transfection efficiency for
luciferase activity was normalized to Renilla luciferase (pRL-null vector) activity. The y-axis shows relative luciferase unit (firefly luciferase unit/Renilla luciferase
unit) by the fold increase in PAH treatment over vehicle treatment. The results are expressed as mean ± SD of four independent transfections and different letters
indicate significant difference (Tukey’s multiple comparison test, p < 0.05). ANP, acenaphthene; BP, biphenylene; 1-MA, 1-methylanthracene; NAP, naphthalene.
Other abbreviations are listed in Figure 1B. (C) The transfected cells were treated with the indicated concentration of BaA for 24 h and luciferase activity was
measured. t-test, **p < 0.01; ***p < 0.001 compared to vehicle.
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FIG. 3. PAH effects on PPARa transactivation in the promoter containing
PPRE sites in A549 cells. (A) Schematic diagram of pCDNA3-mPPARa
expression vector and pPPREX3-TK-Luc reporter vector. (B) A549 cells were
transfected and the cells were treated with either vehicle or indicated BaA for
24 h. *p < 0.05 compared to vehicle. Luciferase activity was measured as
described above.
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chemicals, including the ubiquitous polycyclic aromatic
hydrocarbons (PAHs). A number of PAHs have been known
to affect several chronic diseases, including cancer and
cardiovascular disease, in experimental animals following
oral, pulmonary, dermal, or subcutaneous administration.
Most of the biological effects of PAHs are considered to be
mediated via aryl hydrocarbon receptor (AhR)-dependent
gene expression (Nebert et al., 2000). PAHs also cause
oxidative DNA damage and DNA adduct formation, which
is the most widely accepted mechanisms of PAH-induced
tumorigenesis and cardiovascular disease (Lee and Blair,
2001; Toraason et al., 2001; Wogan et al., 2004). Compared
to genotoxicity or AhR-mediated toxicities of PAHs, knowl-
edge about the nongenotoxic effects of PAHs remains to be
elucidated. The major goal of our investigation was to
determine the cellular mechanisms that are induced by PAHs
in AhR independent manner. EGR-1 and PPARs are the
transcription factors that control many genes in the presence
of stimuli, including chemical compounds. The ability of
select PAHs to activate the EGR-1 gene and to bind to PPARa
and PPARb/d was examined in this study using several PAHs
commonly found in a Superfund site in Chattanooga, Ten-
nessee. We found that some PAHs activated EGR-1 gene and
enhanced PPARa and PPARb/d activity in vitro. The latter
resulted in the suppression of GSK-3b expression, which may
play an important role in tumorigenesis.
EGR-1 can induce expression of a set of vasculature genes,
such as PDGF-A and B chain, bFGF, TGF-b, TNF-a, and
intracellular adhesion molecule-1. Expression of the EGR-1 is
elevated in prostate cancer and correlates with tumor pro-
gression. Thus, EGR-1 is the key mediator in orchestrating the
functional characteristics of the vessel wall and tumorigenesis.
However, EGR-1 can be related to anti-tumorigenesis and pro-
tumorigenesis, depending on cell and tissue types. While EGR-1
induces anti-tumorigenic proteins including p53, PTEN, and
NAG-1 (Baek et al., 2005), EGR-1 is expressed at a higher
level and promotes cell growth in prostate cancer (Eid et al.,
1998; Thigpen et al., 1996). Thus, EGR-1 could play a role in
both cell proliferation and growth arrest. In contrast to EGR-1
functions in tumorigenesis, experimental evidence is emerging
to link EGR-1 to chronic vascular and inflammatory stress
in vivo. The role of EGR-1 in atherosclerosis related to PAH
exposure has not been examined. In this study, EGR-1 was not
up-regulated in heart tissue from mice exposed naturally to
environmental contaminants; however, vascular tissue was not
examined. Further studies are warranted to evaluate the
potential role of EGR-1 in atherosclerosis progression related
to atherosclerosis and heart disease.
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FIG. 4. PAHs effects on PPARb/d activation using luciferase assay. (A) A schematic diagram of the pCMX-Gal4-mPPARd-LBD chimeric gene and the
pMH100X4-TK-Luc reporter vector used in this study. (B) HCT-116 cells were transfected with vectors shown in A, and the cells were treated with 10 lM of
various PAHs for 24 h. Transfection efficiency for luciferase activity was normalized to the Renilla luciferase (pRL-null vector) activity. The y-axis shows relative
luciferase unit (firefly luciferase unit/Renilla luciferase unit). The results are expressed as mean ± SD of three independent transfections and different letters
indicate significant difference (Tukey’s multiple comparision test, p < 0.05). The abbreviations are described in Figure 2B. (C) Transfected cells were treated with
indicated concentrations of BaA for 24 h and luciferase activity was measured. t-test,. **p < 0.01; ***p < 0.001, compared to vehicle treatment.
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PPARa is a key contributor in the processes of peroxisome
proliferation, hypertrophy, cell proliferation, and hepatocarci-
nogenesis in vivo. Its over-expression is observed in advanced
prostate cancer (Collett et al., 2000), and activation of PPARa
promotes cell proliferation in breast cancer cells (Klaunig
et al., 2003; Suchanek et al., 2002). In addition, activation of
PPARa has been demonstrated to modulate many aspects of
lipoprotein metabolism and inflammation in vitro, as well as in
animal and human studies (Israelian-Konaraki and Reaven,
2004). Thus, activation of PPARa may play a role in disease
such as tumorigenesis and atherogenesis. On the other hand,
the activation of PPARb/d plays an anti-apoptotic role in
keratinocytes via transcriptional control of the AKT signaling
pathway (Di-Poi et al., 2002). Genetic disruption of PPARb/d
also decreases the tumorigenicity of human colon cancer cells
transplanted into mice (Park et al., 2001). Our results support
the contention that some PAHs with known carcinogenic
activity are relatively strong PPARa and PPARb/d activators
as assessed by reporter system. These results support that some
PAHs may induce chronic disease through PPAR activation
mechanism other than AhR activation. These results also
suggest that minute differences in PAH structure result in the
activation of two different PPARs.
In this report, we have shown that GSK-3b is suppressed in
heart tissue from mice trapped in a highly contaminated
Superfund site as well as in the FaO cells. GSK-3b is known
to be a negative regulator of cardiac hypertrophy (Hardt and
Sadoshima, 2002), and we have recently reported that AKT/
GSK-3b plays an important role in apoptosis (Yamaguchi et al.,
2004). Therefore, the suppression of GSK-3b by environmental
contaminants such as PAHs may be important in the processes
by which environmental pollution accelerates cardiac disorders
or tumorigenesis such as cardiomyopathy or cancer; however,
further studies may be required to elucidate the exact molecular
mechanism.
In conclusion, our data suggest that some PAHs, particulary
BaA, are able to activate EGR-1 promoter and act as an activator
of PPARa and PPARb/d in vitro. BaA can activate target genes
of PPARa and PPARb/d, thereby repressing the GSK-3b ex-
pression in vitro and in vivo and inducing the CYP4A expression
in vitro. The repression of GSK-3b and activation of EGR-1 by
some PAHs may provide a novel approach to elucidating the
various effects of PAHs on human chronic disease.
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